Hepatocellular carcinoma developed in a living donor after left lobe donation

a case for caution

Toru Ikegami, Tomoharu Yoshizumi, Junji Kawasaki, Tomonari Shimagaki, Hideaki Uchiyama, Yuji Soejima, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although it has been recognized that those who are positive for anti-hepatitis B core antibody (anti-HBcAb) and negative for hepatitis B surface antigen (HBsAg) with normal liver function could be donors for living donor liver transplantation under appropriate prophylaxis, the negative impact of positive HBcAb on such donors themselves has not been reported. We present a case of a living donor with positive HBcAb, who donated his left lobe for his sister with unresectable giant hepatic hemangioma, and the donor himself developed a de novo hepatocellular carcinoma (HCC) 10 years after donation. He had been lost from the follow-up program since 1 year after donation. Imaging studies showed a heterogeneously enhanced mass compatible with HCC, which was 9 cm in size with portal invasion into the anterior portal vein of the remnant liver. Re-laparotomy for hepatectomy with the removal of the tumor thrombus in the anterior portal vein of the remnant liver was carried out, and he is free from recurrence 6 months after surgery on prophylactic sorafenib. At our institute, 58 (9.6%) donors among the 603 living donors were anti-HBcAb positive and anti-HBsAg negative, and we started regular HCC surveillance using sonogram every 6 months for these patients.

Original languageEnglish
Pages (from-to)715-718
Number of pages4
JournalHepatology Research
Volume47
Issue number7
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Living Donors
Hepatitis B Antibodies
Hepatocellular Carcinoma
Tissue Donors
Liver
Hepatitis B Surface Antigens
Portal Vein
Hepatectomy
Hemangioma
Liver Transplantation
Laparotomy
Siblings
Thrombosis
Recurrence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Hepatocellular carcinoma developed in a living donor after left lobe donation : a case for caution. / Ikegami, Toru; Yoshizumi, Tomoharu; Kawasaki, Junji; Shimagaki, Tomonari; Uchiyama, Hideaki; Soejima, Yuji; Maehara, Yoshihiko.

In: Hepatology Research, Vol. 47, No. 7, 01.06.2017, p. 715-718.

Research output: Contribution to journalArticle

Ikegami, Toru ; Yoshizumi, Tomoharu ; Kawasaki, Junji ; Shimagaki, Tomonari ; Uchiyama, Hideaki ; Soejima, Yuji ; Maehara, Yoshihiko. / Hepatocellular carcinoma developed in a living donor after left lobe donation : a case for caution. In: Hepatology Research. 2017 ; Vol. 47, No. 7. pp. 715-718.
@article{46e4ad1f76bb42608cc4c024c8947306,
title = "Hepatocellular carcinoma developed in a living donor after left lobe donation: a case for caution",
abstract = "Although it has been recognized that those who are positive for anti-hepatitis B core antibody (anti-HBcAb) and negative for hepatitis B surface antigen (HBsAg) with normal liver function could be donors for living donor liver transplantation under appropriate prophylaxis, the negative impact of positive HBcAb on such donors themselves has not been reported. We present a case of a living donor with positive HBcAb, who donated his left lobe for his sister with unresectable giant hepatic hemangioma, and the donor himself developed a de novo hepatocellular carcinoma (HCC) 10 years after donation. He had been lost from the follow-up program since 1 year after donation. Imaging studies showed a heterogeneously enhanced mass compatible with HCC, which was 9 cm in size with portal invasion into the anterior portal vein of the remnant liver. Re-laparotomy for hepatectomy with the removal of the tumor thrombus in the anterior portal vein of the remnant liver was carried out, and he is free from recurrence 6 months after surgery on prophylactic sorafenib. At our institute, 58 (9.6{\%}) donors among the 603 living donors were anti-HBcAb positive and anti-HBsAg negative, and we started regular HCC surveillance using sonogram every 6 months for these patients.",
author = "Toru Ikegami and Tomoharu Yoshizumi and Junji Kawasaki and Tomonari Shimagaki and Hideaki Uchiyama and Yuji Soejima and Yoshihiko Maehara",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/hepr.12786",
language = "English",
volume = "47",
pages = "715--718",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Hepatocellular carcinoma developed in a living donor after left lobe donation

T2 - a case for caution

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

AU - Kawasaki, Junji

AU - Shimagaki, Tomonari

AU - Uchiyama, Hideaki

AU - Soejima, Yuji

AU - Maehara, Yoshihiko

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Although it has been recognized that those who are positive for anti-hepatitis B core antibody (anti-HBcAb) and negative for hepatitis B surface antigen (HBsAg) with normal liver function could be donors for living donor liver transplantation under appropriate prophylaxis, the negative impact of positive HBcAb on such donors themselves has not been reported. We present a case of a living donor with positive HBcAb, who donated his left lobe for his sister with unresectable giant hepatic hemangioma, and the donor himself developed a de novo hepatocellular carcinoma (HCC) 10 years after donation. He had been lost from the follow-up program since 1 year after donation. Imaging studies showed a heterogeneously enhanced mass compatible with HCC, which was 9 cm in size with portal invasion into the anterior portal vein of the remnant liver. Re-laparotomy for hepatectomy with the removal of the tumor thrombus in the anterior portal vein of the remnant liver was carried out, and he is free from recurrence 6 months after surgery on prophylactic sorafenib. At our institute, 58 (9.6%) donors among the 603 living donors were anti-HBcAb positive and anti-HBsAg negative, and we started regular HCC surveillance using sonogram every 6 months for these patients.

AB - Although it has been recognized that those who are positive for anti-hepatitis B core antibody (anti-HBcAb) and negative for hepatitis B surface antigen (HBsAg) with normal liver function could be donors for living donor liver transplantation under appropriate prophylaxis, the negative impact of positive HBcAb on such donors themselves has not been reported. We present a case of a living donor with positive HBcAb, who donated his left lobe for his sister with unresectable giant hepatic hemangioma, and the donor himself developed a de novo hepatocellular carcinoma (HCC) 10 years after donation. He had been lost from the follow-up program since 1 year after donation. Imaging studies showed a heterogeneously enhanced mass compatible with HCC, which was 9 cm in size with portal invasion into the anterior portal vein of the remnant liver. Re-laparotomy for hepatectomy with the removal of the tumor thrombus in the anterior portal vein of the remnant liver was carried out, and he is free from recurrence 6 months after surgery on prophylactic sorafenib. At our institute, 58 (9.6%) donors among the 603 living donors were anti-HBcAb positive and anti-HBsAg negative, and we started regular HCC surveillance using sonogram every 6 months for these patients.

UR - http://www.scopus.com/inward/record.url?scp=84983433806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983433806&partnerID=8YFLogxK

U2 - 10.1111/hepr.12786

DO - 10.1111/hepr.12786

M3 - Article

VL - 47

SP - 715

EP - 718

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 7

ER -